Ask AI
KOMET 007
KOMET-007: Long-term Results From the Phase I Trial of Ziftomenib Plus 7 + 3 Intensive Induction Therapy in Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML

Released: July 06, 2026

Activity

Progress
1
Course Completed
Activity Information

Released: July 06, 2026